FGA145
FGA145 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 3.71 μM, 9.82 μM and 53 nM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C23H30N4O5
- 分子量:442.51
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Cathepsin アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
cathepsin L 53 nM (Ki) |
Cathepsin B 206 nM (Ki) |
体外実験
FGA145 reveals weak antiviral activity against SARS-CoV-2 with EC50 of 11.7 μM with low cytotoxicity in Huh-7-ACE2 cells (CC50 over 100 μM)[1].
FGA145 exhibits inhibitory properties towards cysteine proteases RhD, CRZ, Cat L and Cat B, with Kis of 1.63, 12.6, 53 and 206 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Huh-7-ACE2
-
Concentration:0-100 μM
-
Incubation Time:24 h
-
Result:Exhibited a CC50 of over 100 μM.
化学情報
-
分子量 442.51
-
分子式 C23H30N4O5
-
SMILES
O=C(N[C@@H](C[C@@H]1CCNC1=O)/C=C/[N+]([O-])=O)[C@H](CC(C)C)NC(/C=C/C2=CC=CC=C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
FGA145 関連分類
HY-161244 関連分類
Powered by Bioz